228 related articles for article (PubMed ID: 31112621)
1. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
[TBL] [Abstract][Full Text] [Related]
3. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
[TBL] [Abstract][Full Text] [Related]
4. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
[TBL] [Abstract][Full Text] [Related]
8. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
9. Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study.
Meerburg JJ; Andrinopoulou ER; Bos AC; Shin H; van Straten M; Hamed K; Mastoridis P; Tiddens HAWM
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):61-72. PubMed ID: 32073919
[No Abstract] [Full Text] [Related]
10. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
[TBL] [Abstract][Full Text] [Related]
13. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
Eisenberg J; Pepe M; Williams-Warren J; Vasiliev M; Montgomery AB; Smith AL; Ramsey BW
Chest; 1997 Apr; 111(4):955-62. PubMed ID: 9106575
[TBL] [Abstract][Full Text] [Related]
14. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
17. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.
Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
Int J Pharm; 1999 Nov; 189(2):205-14. PubMed ID: 10536249
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers.
Coates AL; MacNeish CF; Lands LC; Meisner D; Kelemen S; Vadas EB
Chest; 1998 Apr; 113(4):951-6. PubMed ID: 9554630
[TBL] [Abstract][Full Text] [Related]
19. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
[TBL] [Abstract][Full Text] [Related]
20. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.
Lenney W; Edenborough F; Kho P; Kovarik JM
J Cyst Fibros; 2011 Jan; 10(1):9-14. PubMed ID: 20884302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
